Makers Laboratories Limited

MAKERSL6

INE987A01010

Pharmaceuticals

Delayed Bombay S.E. Other stock markets 06:39:31 03/06/2024 BST			5-day change	1st Jan Change
128.9 ^INR	+3.24%		+0.19%	-7.00%

05-23	Makers Laboratories Gets Board Nod to Sell Mumbai, India Property to Ipca Laboratories	MT
05-23	Makers Laboratories Limited Reports Earnings Results for the Full Year Ended March 31, 2024	CI

Makers Laboratories Limited Announces the Resignation of Ms. Surbhi Sharma as Company Secretary / Compliance Officer, Effective March 13, 2024

February 15, 2024 at 10:50 am

Makers Laboratories Limited announced the resignation of Ms. Surbhi Sharma as Company Secretary /Compliance Officer. Date of Cessation is March 13, 2024.

Latest news about Makers Laboratories Limited

Makers Laboratories Gets Board Nod to Sell Mumbai, India Property to Ipca Laboratories	05-23	MT
Makers Laboratories Limited Reports Earnings Results for the Full Year Ended March 31, 2024	05-23	CI
Makers Laboratories Limited Reports Earnings Results for the Full Year Ended March 31, 2024	05-23	CI
Makers Laboratories Limited Announces the Resignation of Ms. Surbhi Sharma as Company Secretary / Compliance Officer, Effective March 13, 2024	02-15	CI
Makers Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	02-13	CI
Makers Laboratories Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	11-07	CI
Makers Laboratories Gets Eurasian Economic Union RU GMP Certificate for Ophthalmic Eye Drops Manufacturing Plant	05/10/23	MT
Makers Laboratories Limited Reports Earnings Results for the First Quarter Ended June 30, 2023	14/08/23	CI
Makers Laboratories Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2023	22/05/23	CI
Makers Laboratories Limited Appoints Surbhi Sharma as Company Secretary and Compliance Officer	28/04/23	CI
CARE Affirms BBB+ Rating on Makers Laboratories' Bank Financing; Outlook Stable	08/03/23	MT
Makers Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022	13/02/23	CI
Makers Laboratories Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022	14/11/22	CI
Makers Laboratories Limited Announces Resignation of Rinku Kholakiya as Company Secretary	31/10/22	CI
Makers Laboratories Limited Reports Earnings Results for the First Quarter Ended June 30, 2022	12/08/22	CI
Makers Laboratories Limited Reports Earnings Results for the Full Year Ended March 31, 2022	15/07/22	CI
Makers Laboratories Limited Appoints Rinku Kholakiya as the Company Secretary, Compliance Officer	09/02/22	CI
Makers Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2021	09/02/22	CI
Makers Laboratories Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2021	10/11/21	CI
Makers Laboratories : Swings to Loss in Fiscal Q4	11/06/21	MT
Makers Laboratories Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2021	10/06/21	CI
Makers Laboratories : CARE Reaffirms BBB+ Rating on Makers Laboratories' Bank Facilities; Outlook Stable	23/03/21	MT
Makers Laboratories Limited completed the acquisition of 0.002% stake in Resonance Specialties Limited for INR 0.01 million.	09/12/20	CI
Makers Laboratories Limited Reports Earnings Results for the Second Quarter Ended September 30, 2020	04/11/20	CI
Makers Laboratories Limited made an offer to acquire 26% stake in Resonance Specialties Limited for approximately 170 million.	28/09/20	CI

Chart Makers Laboratories Limited

Duration

Period

More charts

Makers Laboratories Limited is an India-based pharmaceutical company. The Company is engaged in the manufacturing and marketing of pharmaceuticals. The Company operates through the pharmaceuticals segment. Its product portfolio covers a range of general health therapeutic segments. Its formulation brands are Duramol (Paracetamol), Artemak-AB, Loroquin (Chloroquine), Nimuwin (Nimuselide), Coffwin (anti-cough range) and Exylin (Amoxycillin range). Its Inspira retail packs division includes acid regulatory (PPIS), anthelmintics, anti-allergic, anti-asthmatic, anti-biotics, anti-diabetics, anti-diarrheal, anti-emetics and anti-nauseants, anti-fungal, anti-hypertensives, and others. Its Experia bulk packs division includes amoxycillin 250 mg capsules, betamethasone 0.5 mg tablets, cetirizine HCL 10 mg tablets, chloramphenicol capsules 250 mg, chloroquine phosphate 250 mg tablets, chlorpheniramine maleate 4 mg tablets, ciprofloxacin hydrochloride 250 mg tablets, and others.

Sector

Pharmaceuticals

Calendar

08/08/2024 - Q1 2025 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Generic Pharmaceuticals

	1st Jan change	Capi.
MAKERS LABORATORIES LIMITED	-7.00%	8.83M
SUN PHARMACEUTICAL INDUSTRIES LTD.	+15.99%	41.97B
OTSUKA HOLDINGS CO., LTD.	+22.56%	22.34B
SANDOZ GROUP AG	+18.48%	15.25B
CIPLA LIMITED	+16.69%	14B
ZYDUS LIFESCIENCES LIMITED	+49.68%	12.06B
ONO PHARMACEUTICAL CO., LTD.	-10.91%	6.8B
THE MEDICINES COMPANY	-0.05%	6.79B
STADA ARZNEIMITTEL	-8.87%	5.73B
ASPEN PHARMACARE HOLDINGS LIMITED	+14.18%	5.49B

Generic Pharmaceuticals